triazoles has been researched along with Cancer of Oropharnyx in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZG; Diaz, R; Liu, Y; Magliocca, K; Muller, S; Patel, K; Saba, N; Wen, J | 1 |
| Chatterjee, N; Huilgol, NG; Mehta, AR | 1 |
1 trial(s) available for triazoles and Cancer of Oropharnyx
| Article | Year |
|---|---|
An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers.
Topics: Adult; Aged; Humans; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Radiation-Sensitizing Agents; Remission Induction; Triazoles | 1996 |
1 other study(ies) available for triazoles and Cancer of Oropharnyx
| Article | Year |
|---|---|
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Deferoxamine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Oropharyngeal Neoplasms; Papillomaviridae; Triazoles | 2014 |